diclofenac has been researched along with Actinic Keratosis in 64 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ingenol mebutate (IngMeb) and diclofenac sodium (DS) are approved treatments for actinic keratosis (AK)." | 9.27 | Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp. ( Harwood, CA; Larsson, T; Serra-Guillén, C; Skov, T; Stockfleth, E; Østerdal, ML, 2018) |
| "Diclofenac sodium 3% gel (Solaraze®) gained US approval for the treatment of actinic keratosis (AK) more than 10 years ago." | 8.88 | Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety. ( Martin, GM; Stockfleth, E, 2012) |
| " In this work, an electrospun polylactic acid scaffold containing a synthetically obtained Diclofenac prodrug is proposed as a novel substrate for the topical treatment of actinic keratosis." | 7.85 | Electrospun poly-l-lactide scaffold for the controlled and targeted delivery of a synthetically obtained Diclofenac prodrug to treat actinic keratosis. ( Bochicchio, B; Hinderer, S; Pepe, A; Piccirillo, G; Schenke-Layland, K, 2017) |
| " It has been shown to be a safe and effective for treatment of AK on both skin and mucosal lip." | 6.53 | Topical treatment of actinic keratosis with 3.0% diclofenac in 2.5% hyaluronan gel: review of the literature about the cumulative evidence of its efficacy and safety. ( Cozzani, E; Javor, S; Parodi, A, 2016) |
| "Treatment with diclofenac only on the right side of the body resulted in clearing of 55% of all treated lesions, which increased to 60% three months after finishing therapy." | 5.42 | Using photodynamic therapy to estimate effectiveness of innovative combined diclofenac and tazaroten therapy of disseminated actinic keratosis. ( Jurczyszyn, K; Lipinski, A; Nockowski, P; Osiecka, BJ; Sieja, A; Ziółkowski, P, 2015) |
| "Ingenol mebutate (IngMeb) and diclofenac sodium (DS) are approved treatments for actinic keratosis (AK)." | 5.27 | Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp. ( Harwood, CA; Larsson, T; Serra-Guillén, C; Skov, T; Stockfleth, E; Østerdal, ML, 2018) |
| "Diclofenac sodium 3% gel (Solaraze®) gained US approval for the treatment of actinic keratosis (AK) more than 10 years ago." | 4.88 | Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety. ( Martin, GM; Stockfleth, E, 2012) |
| "Diclofenac 3% gel is a widely used topical treatment with proven efficacy in reducing the burden of actinic keratosis (AK); however, clinical benefit might not fully translate in clinical practice as nonadherence is substantial for prolonged treatment regimens." | 4.12 | Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care. ( Bianchi, L; Calzavara-Pinton, P; Campione, E; Carbone, A; Casari, A; Esposito, M; Fargnoli, MC; Fattori, A; Frascione, P; Pellacani, G; Perino, F; Peris, K; Piccerillo, A; Rossi, MT, 2022) |
| "Treatment of actinic keratosis with 3% diclofenac sodium w/w in hyaluronic acid is associated with a concomitant improvement in signs of photodamaged skin." | 3.88 | Assessment of the Effect of 3% Diclofenac Sodium on Photodamaged Skin by Means of Reflectance Confocal Microscopy. ( Alarcón-Salazar, I; Alegre-Sánchez, A; González-Rodríguez, S; Jaén-Olasolo, P; Jiménez-Gómez, N; Muñoz Moreno-Arrones, O; Saceda-Corralo, D; Segurado-Miravalles, G, 2018) |
| " In this work, an electrospun polylactic acid scaffold containing a synthetically obtained Diclofenac prodrug is proposed as a novel substrate for the topical treatment of actinic keratosis." | 3.85 | Electrospun poly-l-lactide scaffold for the controlled and targeted delivery of a synthetically obtained Diclofenac prodrug to treat actinic keratosis. ( Bochicchio, B; Hinderer, S; Pepe, A; Piccirillo, G; Schenke-Layland, K, 2017) |
| "Pretreatment with diclofenac for four weeks improved the clearance rate in one study (24." | 3.01 | Improving the efficacy of photodynamic therapy for actinic keratosis: A comprehensive review of pharmacological pretreatment strategies. ( Andersen, F; Bjerring, P; Haedersdal, M; Lerche, CM; Pihl, C, 2023) |
| "Actinic keratosis is caused by excessive lifetime sun exposure." | 2.82 | Topical Pharmacotherapy for Actinic Keratoses in Older Adults. ( Calzavara-Pinton, I; Calzavara-Pinton, P; Rossi, M; Rovati, C, 2022) |
| "Prevention of nonmelanoma skin cancers remains a health priority due to high costs associated with this disease." | 2.82 | Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm. ( Alberts, DS; Bartels, HG; Bartels, P; Bermudez, Y; Curiel-Lewandrowski, C; Einspahr, JG; Hu, C; Jeter, JM; Myrdal, PB; Stratton, SP; Warneke, JA; Yozwiak, M, 2016) |
| "Diclofenac gel was found to be effective in AK, including the hyperkeratotic type." | 2.78 | Clinical, dermoscopic and immunohistochemical assessment of actinic keratoses and evaluation of the effectiveness of diclofenac therapy with immunohistochemical analysis. ( Çayirli, M; Demiriz, M; Köse, O, 2013) |
| "Treatment with diclofenac in HA is effective and well tolerated during a treatment period of 3 months as well as 6 months." | 2.77 | Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. ( Dirschka, T; Eigentler, TK; Garbe, C; Held, L; Leiter, U; Nashan, D; Pflugfelder, A; Stockfleth, E; Weide, B; Welter, AK, 2012) |
| "AKs must be considered an early squamous cell carcinoma (SCC) for their probable progression into invasive SCC." | 2.66 | Current therapies for actinic keratosis. ( Conforti, C; Corneli, P; di Meo, N; Dianzani, C; Farinazzo, E; Giuffrida, R; Magaton Rizzi, G; Moret, A; Zalaudek, I, 2020) |
| " It has been shown to be a safe and effective for treatment of AK on both skin and mucosal lip." | 2.53 | Topical treatment of actinic keratosis with 3.0% diclofenac in 2.5% hyaluronan gel: review of the literature about the cumulative evidence of its efficacy and safety. ( Cozzani, E; Javor, S; Parodi, A, 2016) |
| "In the future, the treatment of actinic keratosis can be more often done in primary health care." | 2.52 | [Diagnosis and treatment of actinic keratosis]. ( Isoherranen, K; Koskenmies, S; Overmark, M; Pitkänen, S; Saksela, O; Ylitalo, L, 2015) |
| "The cost of topical treatments for actinic keratosis (AK) has historically been evaluated in relation to the number of lesions requiring treatment or simply by the price of a single tube/sachet of the drug used." | 1.51 | Evaluation of the treatment costs and duration of topical treatments for multiple actinic keratosis based on the area of the cancerization field and not on the number of lesions. ( Calzavara-Pinton, P; Hamon, P; Tanova, N, 2019) |
| "Treatment with diclofenac only on the right side of the body resulted in clearing of 55% of all treated lesions, which increased to 60% three months after finishing therapy." | 1.42 | Using photodynamic therapy to estimate effectiveness of innovative combined diclofenac and tazaroten therapy of disseminated actinic keratosis. ( Jurczyszyn, K; Lipinski, A; Nockowski, P; Osiecka, BJ; Sieja, A; Ziółkowski, P, 2015) |
| "Diclofenac 3% in HA was less expensive (Euro 256) than MAL-PDT (Euro 320) and imiquimod (Euro 342)." | 1.36 | Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system. ( Chimenti, S; Colombo, GL; Di Matteo, S; Fargnoli, MC; Frascione, P; Peris, K; Silipo, V, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (7.81) | 29.6817 |
| 2010's | 47 (73.44) | 24.3611 |
| 2020's | 12 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Calzavara-Pinton, P | 4 |
| Calzavara-Pinton, I | 2 |
| Rovati, C | 1 |
| Rossi, M | 1 |
| Arcuri, D | 1 |
| Ramchatesingh, B | 1 |
| Lagacé, F | 1 |
| Iannattone, L | 1 |
| Netchiporouk, E | 1 |
| Lefrançois, P | 1 |
| Litvinov, IV | 1 |
| Pihl, C | 1 |
| Lerche, CM | 1 |
| Andersen, F | 1 |
| Bjerring, P | 1 |
| Haedersdal, M | 1 |
| Gollnick, H | 1 |
| Dirschka, T | 4 |
| Ostendorf, R | 1 |
| Kerl, H | 2 |
| Kunstfeld, R | 1 |
| Schmitz, L | 2 |
| Hansen, JB | 1 |
| Bastian, M | 2 |
| Larsson, T | 4 |
| Stockfleth, E | 9 |
| Arisi, M | 1 |
| Zane, C | 3 |
| Polonioli, M | 1 |
| Tomasi, C | 1 |
| Moggio, E | 1 |
| Cozzi, C | 1 |
| Soglia, S | 1 |
| Caravello, S | 1 |
| Venturini, M | 1 |
| Rossi, MT | 3 |
| Calzavara-Pinton, PG | 3 |
| Dianzani, C | 1 |
| Conforti, C | 1 |
| Giuffrida, R | 1 |
| Corneli, P | 1 |
| di Meo, N | 1 |
| Farinazzo, E | 1 |
| Moret, A | 1 |
| Magaton Rizzi, G | 1 |
| Zalaudek, I | 1 |
| Koch, F | 1 |
| Salva, KA | 1 |
| Wirtz, M | 1 |
| Hadaschik, E | 1 |
| Varaljai, R | 1 |
| Schadendorf, D | 1 |
| Roesch, A | 1 |
| Sinclair, R | 1 |
| Baker, C | 1 |
| Spelman, L | 1 |
| Supranowicz, M | 1 |
| MacMahon, B | 1 |
| Eisen, DB | 1 |
| Asgari, MM | 1 |
| Bennett, DD | 1 |
| Connolly, SM | 1 |
| Dellavalle, RP | 1 |
| Freeman, EE | 1 |
| Goldenberg, G | 1 |
| Leffell, DJ | 1 |
| Peschin, S | 1 |
| Sligh, JE | 1 |
| Wu, PA | 1 |
| Frazer-Green, L | 1 |
| Malik, S | 1 |
| Schlesinger, TE | 1 |
| Perino, F | 1 |
| Fattori, A | 1 |
| Piccerillo, A | 1 |
| Bianchi, L | 1 |
| Fargnoli, MC | 2 |
| Frascione, P | 2 |
| Pellacani, G | 4 |
| Carbone, A | 1 |
| Campione, E | 1 |
| Esposito, M | 1 |
| Casari, A | 1 |
| Peris, K | 4 |
| Beutner, C | 1 |
| Forkel, S | 1 |
| Kreipe, K | 1 |
| Geier, J | 1 |
| Buhl, T | 1 |
| Athanasakis, K | 1 |
| Boubouchairopoulou, N | 1 |
| Tarantilis, F | 1 |
| Tsiantou, V | 1 |
| Kontodimas, S | 1 |
| Kyriopoulos, J | 1 |
| Tolley, K | 2 |
| Argenziano, G | 1 |
| Ryttig, L | 1 |
| Norrlid, H | 1 |
| Norlin, JM | 1 |
| Holmstrup, H | 1 |
| Malmberg, I | 1 |
| Sartorius, K | 1 |
| Thormann, H | 1 |
| Jemec, GBE | 1 |
| Ragnarson Tennvall, G | 1 |
| Harwood, CA | 2 |
| Serra-Guillén, C | 2 |
| Østerdal, ML | 2 |
| Skov, T | 2 |
| Malvehy, J | 2 |
| Puig, S | 2 |
| Bagatin, E | 1 |
| Wollina, U | 1 |
| Gaber, B | 1 |
| Koch, A | 1 |
| Gupta, G | 1 |
| Segert, MH | 1 |
| Kost, R | 1 |
| Sternberg, J | 1 |
| Gambichler, T | 1 |
| Segurado-Miravalles, G | 1 |
| Jiménez-Gómez, N | 1 |
| Muñoz Moreno-Arrones, O | 1 |
| Alarcón-Salazar, I | 1 |
| Alegre-Sánchez, A | 1 |
| Saceda-Corralo, D | 1 |
| Jaén-Olasolo, P | 1 |
| González-Rodríguez, S | 1 |
| de Oliveira, ECV | 1 |
| da Motta, VRV | 1 |
| Pantoja, PC | 1 |
| Ilha, CSO | 1 |
| Magalhães, RF | 1 |
| Galadari, H | 1 |
| Leonardi, GR | 1 |
| Mazzella, C | 1 |
| Greco, V | 1 |
| Costa, C | 1 |
| Scalvenzi, M | 1 |
| Russo, D | 1 |
| Savastano, R | 1 |
| Staibano, S | 1 |
| Fabbrocini, G | 1 |
| Cantisani, C | 1 |
| Paolino, G | 1 |
| Scarnò, M | 1 |
| Didona, D | 1 |
| Tallarico, M | 1 |
| Moliterni, E | 1 |
| Losco, L | 1 |
| Cantoresi, F | 1 |
| Mercuri, SR | 1 |
| Bottoniτ, U | 1 |
| Calvieri, S | 1 |
| Tanova, N | 1 |
| Hamon, P | 1 |
| Tampucci, S | 1 |
| Carpi, S | 1 |
| Digiacomo, M | 1 |
| Polini, B | 1 |
| Fogli, S | 1 |
| Burgalassi, S | 1 |
| Macchia, M | 1 |
| Nieri, P | 1 |
| Manera, C | 1 |
| Monti, D | 1 |
| Herms, F | 1 |
| Gupta, AK | 1 |
| Paquet, M | 1 |
| Samrao, A | 1 |
| Cockerell, CJ | 1 |
| Peserico, A | 2 |
| Neri, L | 2 |
| Calzavara Pinton, P | 2 |
| Catricalà, C | 2 |
| Pimpinelli, N | 2 |
| Facchinetti, E | 1 |
| Specchia, C | 1 |
| Roldán-Marín, R | 1 |
| Iglesias-García, P | 1 |
| Díaz, A | 1 |
| Javor, S | 2 |
| Chimenti, S | 2 |
| Patrizi, A | 1 |
| Stingeni, L | 1 |
| Cavicchini, S | 1 |
| Sala, R | 1 |
| Rongioletti, F | 1 |
| Parodi, A | 2 |
| Kemmett, D | 1 |
| Thybo, S | 1 |
| Nasr, R | 1 |
| Smethurst, H | 1 |
| Osiecka, BJ | 1 |
| Jurczyszyn, K | 1 |
| Nockowski, P | 1 |
| Lipinski, A | 1 |
| Sieja, A | 1 |
| Ziółkowski, P | 1 |
| Isoherranen, K | 1 |
| Koskenmies, S | 1 |
| Overmark, M | 1 |
| Ylitalo, L | 1 |
| Saksela, O | 1 |
| Pitkänen, S | 1 |
| Werner, RN | 1 |
| Jacobs, A | 1 |
| Rosumeck, S | 1 |
| Erdmann, R | 1 |
| Sporbeck, B | 1 |
| Nast, A | 1 |
| Cozzani, E | 1 |
| Jeter, JM | 1 |
| Curiel-Lewandrowski, C | 1 |
| Stratton, SP | 1 |
| Myrdal, PB | 1 |
| Warneke, JA | 1 |
| Einspahr, JG | 1 |
| Bartels, HG | 1 |
| Yozwiak, M | 1 |
| Bermudez, Y | 1 |
| Hu, C | 1 |
| Bartels, P | 1 |
| Alberts, DS | 1 |
| Nisticò, S | 1 |
| Torchia, V | 1 |
| Gliozzi, M | 1 |
| Bottoni, U | 1 |
| Del Duca, E | 1 |
| Muscoli, C | 1 |
| Pacou, M | 1 |
| Szeimies, RM | 1 |
| Piccirillo, G | 1 |
| Bochicchio, B | 1 |
| Pepe, A | 1 |
| Schenke-Layland, K | 1 |
| Hinderer, S | 1 |
| Vlachou, C | 1 |
| Kanelleas, AI | 1 |
| Martin-Clavijo, A | 1 |
| Berth-Jones, J | 1 |
| Mastrolonardo, M | 1 |
| Marks, S | 1 |
| Varma, R | 1 |
| Cantrell, W | 1 |
| Chen, SC | 1 |
| Gold, M | 1 |
| Muellenhoff, M | 1 |
| Elewski, B | 1 |
| Van der Geer, S | 1 |
| Krekels, GA | 1 |
| Ulrich, C | 1 |
| Bierhoff, E | 1 |
| Pflugfelder, A | 2 |
| Garbe, C | 2 |
| Micali, G | 1 |
| Lacarrubba, F | 1 |
| Dinotta, F | 1 |
| Massimino, D | 1 |
| Nasca, MR | 1 |
| Shoimer, I | 1 |
| Rosen, N | 1 |
| Muhn, C | 1 |
| Fenske, NA | 1 |
| Spencer, J | 1 |
| Adam, F | 1 |
| Colombo, GL | 1 |
| Di Matteo, S | 1 |
| Silipo, V | 1 |
| Huang, WW | 1 |
| Clark, AR | 1 |
| Welter, AK | 1 |
| Leiter, U | 1 |
| Weide, B | 1 |
| Held, L | 1 |
| Eigentler, TK | 1 |
| Nashan, D | 1 |
| Akarsu, S | 1 |
| Aktan, S | 1 |
| Atahan, A | 1 |
| Koç, P | 1 |
| Özkan, S | 1 |
| Zwingers, T | 1 |
| Willers, C | 1 |
| Maltusch, A | 1 |
| Röwert-Huber, J | 1 |
| Matthies, C | 1 |
| Lange-Asschenfeldt, S | 1 |
| Martin, GM | 1 |
| Esmann, S | 1 |
| Jemec, GB | 1 |
| Liebman, TN | 1 |
| Stein, JA | 1 |
| Polsky, D | 1 |
| Çayirli, M | 1 |
| Köse, O | 1 |
| Demiriz, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma[NCT01453179] | Phase 4 | 221 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp[NCT02406014] | Phase 4 | 502 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm[NCT00601640] | Phase 2 | 184 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil[NCT02938715] | 26 participants (Actual) | Interventional | 2016-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change scores were computed by subtracting baseline histologic score from End of Study histologic score. Slides were formalin fixed. Histologic Score has been developed by this research group over the course of Grant (reference below). A standardized form captures data on the following criteria: basal or suprabasilar pleomorphism (atypia); inflammation; hyperkeratosis; parakeratosis. The atypia and inflammation were rated as: none (0), mild to moderate(1), and severe (2). The remaining criteria were rated as present (1) or absent (0). Histologic Scores were computed by adding together the codes for the histologic criteria. Higher scores reflected higher level of epidermal /dermal damage. (NCT00601640)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| Eflornithine Hydrochloride | 0.33 |
| Diclofenac Sodium | 0.26 |
| Eflornithine Hydrochloride/Diclofenac Sodium | 0.64 |
Putrescine is measured in nmole/g skin per biopsy. Baseline and End of Study biopsies were measured and the change was produced by subtracting baseline levels from End of Study levels. There was one baseline biopsy and one End of Study biopsy per participant. (NCT00601640)
Timeframe: 3 months
| Intervention | nmol/g skin (Mean) |
|---|---|
| Eflornithine Hydrochloride | 0.03 |
| Diclofenac Sodium | 1.45 |
| Eflornithine Hydrochloride/Diclofenac Sodium | 0.2 |
Adverse events were compared across three treatment groups by severity determined by the clinician. All adverse events were resolved by the end of follow up. (NCT00601640)
Timeframe: 3 months
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Burning and Stinging None | Burning and stinging Mild | burning and stinging Moderate | Burning and Stinging Severe | Pruritis None | Pruritis Mild | Pruritis Moderate | Pruritis Severe | Rash, Redness. Erythema-None | Rash, Redness. Erythema-Mild | Rash, Redness. Erythema-Moderate | Rash, Redness. Erythema-Severe | |
| Diclofenac Sodium | 44 | 8 | 0 | 0 | 33 | 12 | 6 | 1 | 34 | 10 | 8 | 0 |
| Eflornithine Hydrochloride | 48 | 4 | 0 | 0 | 42 | 9 | 1 | 0 | 46 | 5 | 1 | 0 |
| Eflornithine Hydrochloride/Diclofenac Sodium | 48 | 3 | 1 | 0 | 40 | 6 | 6 | 0 | 40 | 7 | 5 | 0 |
18 reviews available for diclofenac and Actinic Keratosis
| Article | Year |
|---|---|
Topical Pharmacotherapy for Actinic Keratoses in Older Adults.
Topics: Aged; Diclofenac; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Treatment Outcome | 2022 |
Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review.
Topics: Aminolevulinic Acid; Diclofenac; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemother | 2023 |
Improving the efficacy of photodynamic therapy for actinic keratosis: A comprehensive review of pharmacological pretreatment strategies.
Topics: Aminolevulinic Acid; Diclofenac; Fluorouracil; Humans; Keratosis, Actinic; Photochemotherapy; Photos | 2023 |
Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials.
Topics: Adjuvants, Immunologic; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Dic | 2020 |
Current therapies for actinic keratosis.
Topics: Aftercare; Carcinoma, Squamous Cell; Chemexfoliation; Cryotherapy; Curettage; Dermoscopy; Diclofenac | 2020 |
A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies.
Topics: Antineoplastic Agents; Diclofenac; Disease Progression; Diterpenes; Fluorouracil; Humans; Imiquimod; | 2021 |
Guidelines of care for the management of actinic keratosis.
Topics: Diclofenac; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy | 2021 |
Actinic keratosis - review for clinical practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cry | 2019 |
Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Topics: Administration, Cutaneous; Animals; Apoptosis; Dermatologic Agents; Diclofenac; Diterpenes; Humans; | 2018 |
Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review.
Topics: Adjuvants, Immunologic; Aged; Aminolevulinic Acid; Aminoquinolines; Anti-Inflammatory Agents, Non-St | 2013 |
Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents.
Topics: Administration, Topical; Aminoquinolines; Cryotherapy; Diclofenac; Dose-Response Relationship, Drug; | 2013 |
[Diagnosis and treatment of actinic keratosis].
Topics: Administration, Topical; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Ag | 2015 |
Topical treatment of actinic keratosis with 3.0% diclofenac in 2.5% hyaluronan gel: review of the literature about the cumulative evidence of its efficacy and safety.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Dermatologic Agents; Diclofenac; | 2016 |
Bucher's indirect comparison of daylight photodynamic therapy with methyl aminolevulinate cream versus diclofenac plus hyaluronic acid gel for the treatment of multiple actinic keratosis.
Topics: Adjuvants, Immunologic; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Ge | 2016 |
Topical treatment of field cancerization.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Diclofenac; Fluorouraci | 2009 |
Treating skin cancer with topical cream.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Diclofenac; | 2010 |
Actinic keratoses: past, present and future.
Topics: Adjuvants, Immunologic; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamou | 2010 |
Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety.
Topics: Administration, Cutaneous; Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Apoptos | 2012 |
14 trials available for diclofenac and Actinic Keratosis
| Article | Year |
|---|---|
Treatment responder analysis in actinic keratosis: can it lead the way to individualized choice of treatment?
Topics: Aged; Diclofenac; Diterpenes; Female; Humans; Keratosis, Actinic; Male; Middle Aged; Treatment Outco | 2021 |
Effects of MAL-PDT, ingenol mebutate and diclofenac plus hyaluronate gel monitored by high-frequency ultrasound and digital dermoscopy in actinic keratosis - a randomized trial.
Topics: Aminolevulinic Acid; Dermoscopy; Diclofenac; Diterpenes; Humans; Keratosis, Actinic; Photochemothera | 2020 |
Efficacy of cold atmospheric plasma vs. diclofenac 3% gel in patients with actinic keratoses: a prospective, randomized and rater-blinded study (ACTICAP).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Gels; Humans; Keratosis, Actinic; Plasma Gases; | 2020 |
Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Dermatologic Agents; Diclofenac; Diterpen | 2018 |
PHOTODYNAMIC TREATMENT WITH NANOEMULSIFIED 5-AMINOLEVULINIC ACID AND NARROW BAND RED LIGHT FOR FIELD CANCERIZATION DUE TO OCCUPATIONAL EXPOSURE TO ULTRAVIOLET LIGHT IRRADIATION.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Sq | 2018 |
Sequential methyl-aminolevulinate daylight photodynamic therapy and diclofenac plus hyaluronic acid gel treatment for multiple actinic keratosis evaluation.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; F | 2018 |
A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cost-Benefit Analysis; Diclofenac; Drug Combina | 2014 |
Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Di | 2016 |
Treatment of actinic keratoses on the dorsum of the hands: ALA-PDT versus diclofenac 3% gel followed by ALA-PDT. A placebo-controlled, double-blind, pilot study.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Diclo | 2009 |
Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Anti-Inflammatory Agents, | 2010 |
Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Germany; Human | 2012 |
Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminoquinolines; Anti-Inflammatory Agents | 2011 |
Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diclofe | 2011 |
Clinical, dermoscopic and immunohistochemical assessment of actinic keratoses and evaluation of the effectiveness of diclofenac therapy with immunohistochemical analysis.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Biomarkers; Cell Proliferation; Chi-Squar | 2013 |
32 other studies available for diclofenac and Actinic Keratosis
| Article | Year |
|---|---|
Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Keratosis, Actinic; Longitudinal Studie | 2022 |
Contact allergy to topical diclofenac with systemic tolerance.
Topics: Administration, Oral; Administration, Topical; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2022 |
Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece.
Topics: Aminoquinolines; Cost-Benefit Analysis; Diclofenac; Diterpenes; Greece; Humans; Imiquimod; Keratosis | 2017 |
Pharmacoeconomic evaluations in the treatment of actinic keratoses.
Topics: Carcinoma, Squamous Cell; Diclofenac; Diterpenes; Economics, Pharmaceutical; Humans; Italy; Keratosi | 2017 |
Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients.
Topics: Administration, Topical; Aged; Aminoquinolines; Denmark; Diclofenac; Diterpenes; Drug Administration | 2018 |
Response to 'Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp'.
Topics: Diclofenac; Diterpenes; Humans; Keratosis, Actinic; Scalp | 2018 |
Response to 'Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp': reply from the authors.
Topics: Diclofenac; Diterpenes; Humans; Keratosis, Actinic; Scalp | 2018 |
Treating actinic keratosis: assessment of effectiveness, discomfort, costs and follow-up.
Topics: Diclofenac; Diterpenes; Follow-Up Studies; Humans; Keratosis, Actinic; Scalp | 2018 |
Diclofenac Sodium 3% in Hyaluronic Acid 2.5% Gel Significantly Diminishes the Actinic Keratosis Area and Severity Index.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Dermatologic Agents; Diclofenac; Female; Follow- | 2018 |
Assessment of the Effect of 3% Diclofenac Sodium on Photodamaged Skin by Means of Reflectance Confocal Microscopy.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Dermatologic Agents; Diclofenac; F | 2018 |
Management of clinical and subclinical actinic keratoses with histological and immunohistochemical assessments by confocal microscopy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Diclofenac; Fluorouracil; | 2018 |
Evaluation of the treatment costs and duration of topical treatments for multiple actinic keratosis based on the area of the cancerization field and not on the number of lesions.
Topics: Administration, Topical; Aminolevulinic Acid; Cohort Studies; Cost of Illness; Diclofenac; Diterpene | 2019 |
Diclofenac-Derived Hybrids for Treatment of Actinic Keratosis and Squamous Cell Carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line; Cell Proliferation; Cell Survival; Diclofenac; Humans; | 2019 |
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cost-Benefit Analysis; Cryotherapy; | 2019 |
Key Opinion Leader (KOL) Consensus for actinic keratosis management in Italy: the AKTUAL Workshop.
Topics: Aminoquinolines; Carcinoma, Squamous Cell; Case Management; Clinical Trials as Topic; Cryosurgery; D | 2013 |
Monitoring treatment of field cancerisation with 3% diclofenac sodium 2.5% hyaluronic acid by reflectance confocal microscopy: a histologic correlation.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Diclofenac; Drug Therapy | 2015 |
Physicians' opinions and clinical practice patterns for actinic keratosis management in Italy.
Topics: Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Attitude of Health | 2014 |
Relapsed actinic keratosis evaluation: an observational Italian multicenter prospective study. Does gender have a role?
Topics: Adult; Aged; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cohort | 2014 |
A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
Topics: Cost-Benefit Analysis; Cryotherapy; Diclofenac; Diterpenes; Dose-Response Relationship, Drug; Fluoro | 2016 |
Using photodynamic therapy to estimate effectiveness of innovative combined diclofenac and tazaroten therapy of disseminated actinic keratosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dermatologic Agents; Diclofenac; Drug Therapy, Combination; | 2015 |
Methods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International League of Dermatological Societies in cooperation with the European Dermatology Forum.
Topics: Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Cryotherapy; Curettage; Cyclooxyg | 2015 |
Pharmacoeconomy of drugs used in the treatment of actinic keratoses.
Topics: Cost-Benefit Analysis; Diclofenac; Diterpenes; Humans; Italy; Keratosis, Actinic; Quality of Life; T | 2016 |
Electrospun poly-l-lactide scaffold for the controlled and targeted delivery of a synthetically obtained Diclofenac prodrug to treat actinic keratosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Delayed-Action Preparations; Diclofenac; D | 2017 |
Treatment of disseminated superficial actinic porokeratosis with topical diclofenac gel: a case series.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Gels; Hu | 2008 |
Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses.
Topics: Administration, Cutaneous; Aged; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; | 2009 |
Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis.
Topics: Adult; Diclofenac; Gels; Humans; Keratosis, Actinic; Pilot Projects; Porokeratosis; Surveys and Ques | 2009 |
Current management of actinic keratoses.
Topics: Administration, Cutaneous; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic | 2010 |
Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system.
Topics: Administration, Topical; Aminolevulinic Acid; Aminoquinolines; Cost-Benefit Analysis; Decision Trees | 2010 |
Actinic keratosis. Patient-based approaches to adverse event management.
Topics: Administration, Topical; Aminoquinolines; Combined Modality Therapy; Cryotherapy; Dermatologic Agent | 2010 |
Modes of action of diclofenac 3%/hyaluronic acid 2.5% in the treatment of actinic keratosis.
Topics: Adjuvants, Immunologic; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Diclofenac; | 2011 |
Patients' perceptions of topical treatments of actinic keratosis.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Diclofenac | 2014 |
Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: is there a role for these agents?
Topics: Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Cy | 2013 |